As clinical trials are increasingly designed to compare new assets with existing gold standard therapies such as Humira, Keytruda and other high cost reference medicines, the cost of the comparator drug budget is becoming a significant proportion of the total trial budget.

One of our valued clients is a large multinational pharmaceutical company, harnessing new technologies to develop medicines that address unmet medical needs. Their expansive clinical pipeline covers indications where there are already standards of care and multiple lines of potential treatments if the first line is insufficient.